Company intelligence / Profile preview

AvantGuard

Ithaca, New York, United States

Ownership: Private
Development stage: Other

Overview

AvantGuard is advancing a proprietary antimicrobial compound, Avantamine, offering broad-spectrum, long-lasting, and resistance-avoidant effects. It has received multiple NIH grants for preclinical work in infection prevention (surface and medical device disinfection), dermatology (antifungals), and chronic wound management. No clinical results have yet been reported; all activity is currently preclinical and regulatory-facing.[1][5]

Therapeutic areas: EndocrinologyDermatologyInfectious Diseases
Modalities: PolymerAntimicrobial compound
Industry: Biotech

Drug pipeline

2 assets

Avantamine

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Strategic partnership with an unnamed medical device company (pre-commercial)

Beyond the preview

Go deeper on AvantGuard.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AvantGuard.

Explore the full profile